{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-25-000028","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.863495+00:00","generated_at":"2026-05-26T04:51:10.426727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M","bullets":["Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.","Full-year ZORYVE net product revenue $166.5M (+471% YoY); ZORYVE is #1 branded non-steroidal topical in U.S.","Submitted sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5; target action Q4 2025.","Prepaid $100M of $200M term loan; maintains ability to re-draw; cash & securities $228.6M at year-end.","ZORYVE foam for scalp/body psoriasis PDUFA date May 22, 2025; partnered with Odell Beckham Jr. for seborrheic dermatitis awareness."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-25-000028","json":"https://secwatch.observer/filing/0001787306-25-000028.json","markdown":"https://secwatch.observer/filing/0001787306-25-000028.md","text":"https://secwatch.observer/filing/0001787306-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/0001787306-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/arqt-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:51:10.426727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}